Adenosine 12MG/4ML 10S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTKX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,154
Award facts
- Contract value 100% obligated
- $26,153.85 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $26,153.85 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Adenosine 12mg/4ml in quantities of 10 units. The delivery order, issued on January 15, 2026, carries an ultimate completion date of January 15, 2026, and includes no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition vehicle awarded on November 13, 2025, that establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical pharmaceutical supplier within the federal military medical supply chain, with a product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's established performance on numerous delivery orders under the PPV-G GEN V contract, which is structured with a 30-month base period and three 30-month option periods extending through December 31, 2036, positions it to fulfill the diverse and specialized pharmaceutical requirements of military healthcare facilities globally. No subcontractors are identified in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FBTKX?
SPE2DR26FBTKX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FBTKX worth?
The government has obligated $26,154 on SPE2DR26FBTKX.
Is contract SPE2DR26FBTKX an order under another contract?
Yes. SPE2DR26FBTKX is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTKX competed?
The extent of competition for SPE2DR26FBTKX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award